Lymphoma & Myeloma Conference Highlights Importance of Genasense(TM) Target in Cancer Therapy
BERKELEY HEIGHTS, N.J., Oct 3, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) announces that several upcoming presentations will
highlight the central importance of the protein targeted by Genasense, Genta's
lead anticancer compound. The presentations will take place at the scientific
conference, "Lymphoma & Myeloma 2002". The meeting will be held at the Crowne
Plaza Hotel in New York from October 3-5, 2002. A complete agenda of the meeting
can be accessed at: imedex.com
Several relevant presentations include:
Title: "New Molecules in the Treatment of Myeloma: SAHA, Bcl-2
antisense and Gallium"
When: Friday, October 4, 11:50 AM
Presenter: Dr. Rubin Niesvizky, Center for Lymphoma and Myeloma, Weill
Medical College of Cornell University, The New York
Presbyterian Hospitals
Title: "The Role of Bcl-2 in Lymphoma"
When: Friday, October 4, 3:10 PM
Presenter: Randy D. Gascoyne, British Columbia Cancer Agency,
Vancouver, Canada
Title: "Anti-sense Approaches for Lymphoma"
When: Friday, October 4, 5:30 PM
Presenter: Cy A. Stein, Ph.D, Columbia University, College of
Physicians & Surgeons
About Genasense
Genasense works by inhibiting the production of Bcl-2, a protein made by cancer
cells that is thought to block chemotherapy-induced cell death. By reducing the
amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of
current anticancer treatments. |
